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ABSTRACT
In 2013 the European Medicine Agency (EMA) restricted the indication for anti-
EGFR targeted therapy to metastatic colorectal cancer (mCRC) with a wild-type 
RAS gene, increasing the need for reliable RAS mutation testing. We evaluated the 
completeness and reproducibility of RAS-testing in the Netherlands.
From 17 laboratories, tumor DNA of the first 10 CRC cases tested in 2014 in 
routine clinical practice was re-tested by a reference laboratory using a custom next 
generation sequencing panel. In total, 171 CRC cases were re-evaluated for hotspot 
mutations in KRAS, NRAS and BRAF. 
Most laboratories had introduced complete RAS-testing (65%) and BRAF-testing 
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INTRODUCTION
Anti-Epithelial Growth Factor Receptor (EGFR) 
targeted therapy, such as panitumumab and cetuximab, 
is effectively reducing the risk of tumor progression and 
improving overall survival (OS), progression free survival 
(PFS) and quality of life in metastatic colorectal cancer 
(mCRC) patients whose tumor is RAS wild-type [1, 2]. 
Conversely, mCRC patients with mutated RAS tumors 
(KRAS and NRAS mutations) who received panitumumab 
in combination with oxaliplatin-based chemotherapy 
had a significantly worse outcome in OS and PFS [3]. 
This notion has led to a new incentive by the European 
Medicine Agency (EMA) for Vectibix (panitumumab) in 
June 2013 [4] and for Erbitux (cetuximab) in November 
2013 [5], to indicate administration of EGFR targeted 
therapy only to patients with wild-type RAS mCRC. This 
has increased the need for reliable RAS mutation testing 
methods to assure the quality of RAS status determination. 
Most molecular testing methods that are used 
nowadays accurately assess mutational status of 
RAS genes in samples with >30-50% tumor cells, or 
alternatively with 15-25% of mutated alleles in the test 
sample [6, 7]. However, with lower number of mutated 
alleles in the sample, the limit of accurate detection of 
a method declines depending on the test method used 
[8]. Even when using the same method, differences in 
protocols between laboratories can result in different 
outcomes. It has been suggested that the reproducibility 
amongst different testing methods is not as high as 
anticipated for based on previous EQA schemes for KRAS 
exon 2 testing[9]. In a recent study, in 29 out of 182 KRAS 
exon 2 wild-type tumors (15.9%), as assessed with Sanger 
sequencing, a KRAS exon 2 mutation was found with next 
generation sequencing (NGS) [10]. This suggests a higher 
variability in reproducibility between test methods and 
laboratories than initially measured [11]. 
Given the clinical impact of RAS-testing, it is of 
utmost importance to control for reliable performance of 
routine RAS-testing methods used in clinical practice. In 
this study, we evaluated the inter-laboratory agreement 
of RAS-testing amongst 171 mCRC patients of 17 Dutch 
laboratories.
RESULTS
Integration of full RAS-testing in the Netherlands
In January 2014, 11 of 17 participating Dutch 
laboratories had introduced full RAS testing (65%). 
All 17 participating centers performed KRAS exon 2 
(codon 12 and 13) and KRAS exon 3 (codon 61) testing. 
The method most frequently used for KRAS exon 2 was 
Sanger sequencing of PCR products, either directly 
(5 laboratories; 51 samples (29.8%)) or to specify 
the mutation detected with high resolution melting 
(HRM) analysis or to confirm a real-time PCR result (7 
laboratories; 70 samples (40.9%)) [Table 1]. 
Of the 6 laboratories that had not introduced full 
RAS-testing, one laboratory did not test for NRAS exon 
2, 3, 4 and KRAS exon 4, three had not introduced NRAS 
exon 4 (codon 117 and 146), one laboratory did not 
have KRAS exon 4 codon 117 in their test panel and one 
laboratory did not test for KRAS exon 3 codon 59 [see 
Table 1]. One of these 6 laboratories introduced full RAS 
testing early 2014 and had only tested 3 out of 10 (30%) 
CRC cases with full RAS-testing. 
For full RAS-testing direct Sanger sequencing of 
PCR products was used most often either with or without 
a prescreen (range 35.7% - 49.2%) [Table 1]. The use 
of Mass Spectrometry (Sequenom) or CE-IVD kits 
(Therascreen) was reported by 2 laboratories (11.6%). In 
3 laboratories (17.5%) next generation sequencing (NGS) 
with MiSeq (Illumina) or Ion Torrent (Life technologies) 
was used for RAS testing. In conclusion, full RAS testing 
had been introduced in the majority of laboratories 
participating in this study and relied mostly on Sanger 
sequencing methods. 
Mutation frequencies of KRAS, NRAS and BRAF 
The amount and quality of 167 out of 171 received 
DNA samples was sufficient for successful evaluation by 
the reference laboratory using NGS of at least one of the 
target sites (165 samples for KRAS, 163 for NRAS and 
163 for BRAF; see materials and methods). Overall, in 
102 samples (61.1% (95% CI 53.5 – 68.2)) a mutation 
(71%) by January 2014. The most employed method for all hotspot regions was Sanger 
sequencing (range 35.7 – 49.2%). The reference laboratory detected all mutations that 
had been found in the participating laboratories (n = 92), plus 10 additional mutations. 
This concerned three RAS and seven BRAF mutations that were missed due to incomplete 
testing of the participating laboratory. Overall, the concordance of tests performed by both 
the reference and participating laboratory was 100% (163/163; κ-static 1.0) for RAS and 
100% (144/144; κ-static 1.0) for BRAF. 
Our study shows that RAS and BRAF mutations can be reproducibly assessed using 
a variety of testing methods. 
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Figure 1: Mutation prevalence of KRAS, NRAS and BRAF. A) Pie chart showing all evaluated CRC cases (n = 167; 167 of 171 
samples could be evaluated for at least one of the target sites). Of these CRC cases, 61.1% had a mutation. KRAS mutations alone were 
most frequently observed (43.0%). BRAF mutations were found in 23 CRC cases (All in exon 15; c.1799T>A (p.Val600Glu)). The 95% CI 
was calculated with Jeffry’s method. B) A total of 71 KRAS mutations was found; 59 in KRAS exon 2 (83.2%), 6 in KRAS exon 3 (8.4%), 
and 6 in KRAS exon 4 (8.4%). Gly12Val (29.6%) and Gly12Asp (23.9%) were the most common mutations found followed by Gly13Asp 
(12.7%). C) A total of 8 NRAS mutations was detected of which 2 were detected in exon 2 (Gly12Asp) and 6 in exon 3. The most common 
mutation in NRAS was Gln61Arg (37.5%). 
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in KRAS, NRAS or BRAF was found at the reference 
laboratory [Figure 1A]. 
A KRAS exon 2 mutation was detected in 59 mCRC 
cases (35.8%), other RAS mutations were found in KRAS 
exon 3 (n = 3 (3.6%)), KRAS exon 4 (n = 3 (3.6%)) NRAS 
exon 2 (n = 1 (1.2%)) and NRAS exon 3 (n = 3 (3.6%)). No 
mutations in NRAS exon 4 were detected. This resulted in 
a total 79 RAS mutations (47.6% (95% CI 40.1-55.2)) of 
which only 8 were NRAS mutations. The mean percentage 
of mutated alleles was 42.1% (SD 15.7%) for KRAS and 
46.1% (SD 23.25%) for NRAS [Supplementary Table 
1]. The majority of KRAS mutations affected codon 12 
(70.5%), especially p.Gly12Asp (23.9%) and p.Gly12Val 
were common (29.6%) [Figure 1B]; 5 out of 8 NRAS 
mutations were found in codon 61 (62.5%) [Figure 1C]. 
None of the samples harbored both or more than one 
KRAS and/or NRAS mutation.
BRAF mutations occurred in 23 of 163 CRC cases 
(14.1% (95%CI 9.4-20.1)) [Figure 1A] and were all 
c.1799T>A (p.Val600Glu) mutations in exon 15. The 
mean percentage of mutated alleles for BRAF was 34.5% 
(SD 14.3%) [Supplementary Table 1]. Both KRAS and 
NRAS mutations in our sample were mutually exclusive 
with BRAF mutations (OR =2.15 (95%CI 1.80-2.57); Chi-
square p<0.01). 
High concordance of RAS and BRAF-testing 
For 167 samples that could be evaluated by the 
reference laboratory, all mutations that had been found in 
the participating laboratories were verified. In addition, 
the reference lab detected three RAS and seven BRAF 
mutations that had not been detected in the participating 
laboratories. This concerned mutations in KRAS exon 
4 (c.436G>A; p.Ala146Thr), NRAS exon 2 (c.35G>A; 
p.Gly12Asp), NRAS exon 3 (c.181C>A; p.Gln61Lys) and 
seven mutations in BRAF (c.1799T>A; p.Val600GLu) 
that the participating laboratory had not tested for 
[Table 2]. Altogether, the inter-laboratory agreement for 
tests performed by both the reference and participating 
laboratory was 100% (163/163) (κ statistic 1.0) for full 
RAS and 100% (144/144) (κ statistic 1.0) for BRAF-testing 
[Table 3]. All three additionally found RAS-mutations were 
reported back to the respective participating laboratory, 
and were confirmed with their newly installed Sanger 
sequencing or NGS approaches for the respective target 
sites.
Association between percentage of neoplastic cells 
and mutation detection
Testing sensitivity of RAS-mutations is dependent 
on the percentage of neoplastic cells represented in the 
test sample; low neoplastic cell percentages may result in 
missing of RAS-mutations depending on the technique that 
is used[8]. For 158 samples the percentage of neoplastic 
cells as estimated by the pathologist of the participating 
laboratory was known. The median estimated neoplastic 
cell percentage represented in the DNA samples was 
50% (inter quartile range (IQR)=30). Of the 158 samples, 
47 (29.7%) had neoplastic cell percentages below 40%. 
When comparing the distribution of estimated neoplastic 
cell percentages amongst RAS-mutated (N = 73) and 
RAS-wild-type (N = 85) samples, the median neoplastic 
cell percentage was significantly lower in RAS-mutated 
samples (50.0% (IQR=28) compared to RAS-wild type 
(60.0% (IQR=20)) samples (Mann-Whitney U, p < 0.01) 
[Figure 2]. In RAS-mutated samples, the mean percentage 
of mutated alleles correlated with the percentage of 
neoplastic cells in the test sample (Pearson r = 0.433 (p 
< 0.01) for KRAS and Pearson r = 0.792 (p = 0.034) for 
NRAS; Supplementary figure 1). 
The frequency of RAS mutations amongst samples 
with neoplastic cell percentages ≤40% was significantly 
higher than in samples >40% neoplastic cells (OR 2.45 
(95%CI 1.22 – 4.94), chi-square p = 0.011). A similar 
result was obtained when lowering the cut-off to 30 or 
20% neoplastic cells, suggesting that the sensitivity of the 
RAS mutation analyses were adequate, even in samples 
with low neoplastic cells. However, care should be taken 
while reporting wild-type in samples with low neoplastic 
cells depending on the lower limit of detection of the 
technique applied to prevent reporting false-negatives.
DISCUSSION
Our results show an excellent concordance (100%, 
kappa 1.0) of RAS-test results of the reference lab oratory 
and 17 other Dutch laboratories in routine clinical practice, 
despite differences in testing methods used. Overall, full 
RAS-testing of KRAS exon 2, 3 and 4 and NRAS exon 
2, 3 and 4 has been introduced in the majority of the 
participating laboratories (65%). Three RAS mutations 
and seven BRAF mutation were missed due to incomplete 
testing.
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Figure 2: Neoplastic cell percentage in RAS-mutated and RAS-wild-type tumors. The distribution of the estimated percentage 
of tumor cells in the test sample was compared between RAS-mutated and RAS-wild type CRC cases. Frequency of CRC cases is shown 
on the Y-axis; the X-axis represents the percentage of neoplastic cells. Mann-Whitney U test of the comparison indicates that the median 
neoplastic cell percentage of RAS-mutated mCRC cases is significantly lower (Median 50 (IQR 28), Mean Rank = 66,65) than RAS-
wild-type mCRC cases (Median 60 (IQR 20), Mean Rank = 90,54; p = 0.001) and thus that the populations have distinct neoplastic cell 
percentage distributions.
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The frequency of RAS mutations reported in 
our study matches those previously reported in the 
literature. Approximately 35-45% of all CRCs contain 
RAS-mutations in KRAS exon 2 [3, 12–16], whereas 
approximately 10% of RAS-mutations occurs in KRAS 
exons 3 and 4 or NRAS exons 2, 3 and 4 [3, 17–19]. In 
addition, KRAS, NRAS and BRAF mutations have a 
strong tendency towards mutual exclusivity [20]. BRAF 
mutations occurred in 14% of our samples, which seems 
higher than the reported 9% in the Cancer Genome Atlas 
[20]. While BRAF mutation analysis is incorporated 
in the test repertoire of most laboratories (71%), some 
laboratories only test for BRAF on special request by the 
physician when tumors were previously tested RAS wild-
type. BRAF mutation frequency amongst KRAS exon 2 
wild-type tumors is reported to be around 8-15% [10, 18]. 
To assure accurate determination of RAS wild-
type and mutant status, the quality of mutation detection 
for each KRAS and NRAS exon needs to be determined. 
Reproducibility is one of the measures that signify the 
quality of diagnostic tests. Poor reproducibility can 
have several causes: 1) the testing methods used have a 
difference in sensitivity (ability to identify tumors with 
the mutation) or, 2) there is variation between different 
persons/laboratories performing the test (inter-observer 
variability). In a recently published Italian study, it was 
found that amongst KRAS exon 2 wild-type tumors, as 
assessed with Sanger sequencing, a KRAS exon 2 mutation 
was found with NGS in 28 out of 182 mCRC cases 
(15.9%). The difference in sensitivity between the testing 
methods could have partly accounted for the discrepancy 
found in this study [10]. In our study the discrepancy 
between the test results generated in 17 different 
laboratories using a variety of testing methods and the 
reference laboratory using a NGS approach was naught, 
even in samples with a neoplastic cell percentage between 
20-40% and in laboratories using Sanger sequencing. In 
the 2012 KRAS external quality assessment program of 
the European Society of Pathology, less than 5% of all 
samples were wrongly genotyped for KRAS amongst 100 
laboratories in 26 countries[11]. 
Testing sensitivity is reflected by the limit of 
detection of the method, but is also limited by the 
percentage of neoplastic cells represented in the test 
sample. In fact, low neoplastic cell percentage (~10%) led 
to 16 of the 29 false-negatives in the 2012 KRAS EQA 
scheme[11]. For PCR and Sanger sequencing a minimum 
amount of 20-30% of tumor cells is required [21]. Our 
study has high reproducibility even in samples with a low 
neoplastic cell percentage and the percentage of mutated 
alleles correlates with the neoplastic cell content in the 
sample [Supplementary figure 1]. In fact, the percentage 
of RAS mutant samples was significantly higher in samples 
with neoplastic cell percentages below 40%, which 
demonstrates that mutations could also be detected in 
samples with a low neoplastic cell percentage. However, 
this unexpected observation could be merely coincidental 
due to small subgroups and difference in tumor sampling 
in combination with variation in estimating the amount 
of neoplastic cells, which is known to be high among 
pathologists [22, 23]. 
Potential sources of bias in our study could have 
affected the reported reproducibility. First, centers were 
asked to send DNA of the first 10 CRC cases tested in 
2014. Because KRAS exon 2 mutations are the most 
frequent, there were some laboratories where only 
KRAS exon 2 mutations or wild-type RAS-status was 
reported. This could have led to an overestimation of 
the reproducibility because other RAS-mutations were 
not present. Secondly, the likelihood of finding false-
negatives is higher when only wild-type samples are 
re-tested. In this series only 54 samples were wild-type 
for all the tested hotspot mutations and thus could have 
led to an underestimation of false-negative wild-type 
samples. The small number of NRAS-mutations found has 
likely overestimated the reproducibility of this group of 
mutations. Future studies need to verify whether newly 
installed methods reproducibly detect NRAS mutations, 
especially in laboratories that did not report any NRAS 
mutations in the tested CRC panel. 
In conclusion, our study clearly shows that RAS-
status can be reproducibly assessed between laboratories 
in routine clinical practice using similar or different 
testing methods. With constant improvement of testing 
methodologies and quality controls, this offers good 
expectations for the future of molecular testing in mCRC. 
Nevertheless, more in depth analyses with regard to the 
effect of testing sensitivity and the percentage of tumor 
cells in the test sample on RAS mutation detection are 
warranted. 
PATIENTS AND METHODS
Patient selection and data collection
All 22 Dutch institutes that participated in the 
European Quality Assurance (EQA) scheme of the 
European society of pathology (ESP) in 2013 were 
invited to participate in the study. Seventeen laboratories 
responded and were subsequently requested to send 10 
µl DNA (≥30 ng) of the first 10 mCRCs tested in routine 
diagnostics for anti-EGFR targeted therapy from 1st 
January 2014. In addition, each laboratory was asked to 
indicate the testing method used, the mutations tested for 
and the percentage of neoplastic cells in the tissue the 
DNA was extracted from. Moreover, the KRAS, NRAS and 
BRAF mutations found by the participating laboratories 
were reported and stored by a third party until study 
end. Retesting of the samples at the reference laboratory 
was performed blinded. Approval by a medical ethics 
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committee was not required. All data were reported in de-
identified form and are in agreement with the Dutch Data 
Protection Act.
Next generation sequencing
A total of 171 DNA samples received from the 
participating laboratories (one lab contributed 11 samples) 
were quantified on the Qubit platform (Life technologies). 
Samples with a DNA concentration below 0.5 ng/µl were 
excluded from further analysis. Bar-coded libraries were 
prepared from 10-100 ng DNA using a custom AmpliSeq 
panel targeting frequently mutated regions in the KRAS, 
NRAS, EGFR, PIK3CA, ERBB2, AKT1, BRAF genes and 
the AMELX/Y gene as a control gene to determine the sex 
of the patient. Libraries were equimolar pooled and clonal 
amplification was performed by emulsion PCR using the 
One Touch 2 system (Life Technologies) and subsequently 
run on the Ion Torrent Personal Genome Machine (Life 
Technologies). Torrent Suite Software v.3.4.2. was used 
to pre-process the raw data. Subsequent mapping and 
variant calling was performed using SeqNext software 
v.4.1.2. (JSI medical systems GmbH). The following 
genes and exons were included in the data analysis: KRAS 
exon 2, 3 and 4 (NM_004985.3), NRAS exon 2,3 and 4 
(NM_002524.3) and BRAF exon 15 (NM_004333.4). The 
minimum read coverage allowed to call mutant alleles 
was set at 100 reads. In general, read coverage was more 
than 500 resulting in a sensitivity of 5% mutant alleles. 
For a read coverage between 100-500 reads, a limit of 
10% mutant alleles was employed. When coverage was 
low or mutation calling could not be established due to 
other technical reasons, the run was repeated. When 
there was still insufficient coverage of the target sites 
after repeating the run, the samples were excluded from 
analysis. In total 6 KRAS, 8 NRAS and 8 BRAF target 
sites had insufficient coverage due to low amount or poor 
DNA quality. Therefore, we could successfully evaluate a 
total of 165 KRAS, 163 NRAS and 163 BRAF target sites; 
for 167 samples at least one of the target sites could be 
successfully evaluated. 
Data analysis
Variants were filtered for known SNPs and 
systematic sequencing artifacts. Next, the somatic 
mutations found in the DNA-samples by the reference 
laboratory were compared with the mutations originally 
found by the participating laboratories to assess the 
percentage of agreement of the results. The mutations 
were compared at the genotype level. Each participating 
pathology center was informed about their individual 
results and performance. 
Statistical analysis
All statistical analyses were performed in IBM 
SPSS statistics version 20. Mutation frequencies were 
calculated for KRAS, NRAS and BRAF. Binominal 
confidence intervals were calculated using the Jeffrey’s 
interval. The detected mutation(s) in the DNA-samples at 
the genotype level were compared between the reference 
laboratory and the participating laboratories and expressed 
as percentage agreement. Data were evaluated for hotspot 
mutations in KRAS exon 2, 3 and 4, NRAS exon 2, 3 and 
4 and BRAF exon 15. Concordance (inter-laboratory 
agreement, kappa-statistic[24]) was only calculated when 
the mutation was targeted in the test panel of both the 
reference and participating laboratory. Odds ratios with 
95% confidence intervals and chi-square statistics were 
calculated to evaluate associations between RAS-mutations 
and BRAF. The distribution of tumor cell percentage in the 
DNA-samples amongst RAS-mutated and RAS-wild-type 
samples was assessed with the Mann-Whitney U test.
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